CURRICULUM VITAE Present Position Address Phone/Fax:

Transcription

CURRICULUM VITAE
Present Position Associate Professor of Internal Medicine
Address
4th Department of Internal Medicine, ATTIKON University Hospital, 124 64
Athens
Phone/Fax:
0030 210 58 31 994/00330 210 53 26 446
E-mail:
egiamarel@med.uoa.gr
Date of Birth
Athens, February 1971
Marital Status
Married, with four children
MEDICAL STUDIES
Medical Degree
University of Athens, Medical School, June 1994, “Grade A”
Medical
Athens, August 1994
Licensure
ECFMG
Educational Commission for Foreign Medical Graduates
Certification/USA, March 1995
PhD
University of Athens, Medical School, February 1998, “Grade A” on “The
in vitro activity of polyunsaturated fatty acids on Gram-negative bacteria”
Research
2001 on “The in vitro activity of polyunsaturated fatty acids on GramFellowship
negative bacteria” by the European Society of Clinical Microbiology and
Infectious Diseases
SPECIALIZATION IN INTERNAL MEDICINE AND INFECTIOUS DISEASES
HIV Medicine
• March 1995-September 1996, AIDS Unit, Athens General Hospital
“G.Gennimatas”
Internal
• November 1997-March 1998, 2nd Department of Internal Medicine, 251
Medicine
Air Force General Hospital
• August 1998-September 2001, 1st Department of Propedeutic Medicine,
Laikon University Hospital
• September 2001-April 2003, 4th Department of Internal Medicine,
Sismanogleion General Hospital
Boards
• December 2004, Internal Medicine
Immunology of
• November 2006-May 2007, Department of Internal Medicine and Center
Infectious
of Infectious Diseases, Radboud University, Nijmegen, The
Diseases
Netherlands
ACADEMIC CAREER
• September 2001-November 2005: Lecturer of Internal Medicine; Athens Medical School,
Greece
• December 2005-May 2012: Assistant Professor of Internal Medicine; Athens Medical
School, Greece
• June 2012-today: Associate Professor of Internal Medicine; Athens Medical School,
Greece
• October 2003-today: Supervisor of “Immunology of Infectious Diseases”, Laboratory and
Out-Patients, ATTIKON University Hospital, Athens, Greece
• October 2003-today: Head of the Center for Experimental Animals, ATTIKON University
Hospital, Greece
• April-September 2012: February-August 2013: Guest Professor, Jena University Hospital
and Center for Sepsis Control and Care (CSCC), Jena, Germany
FIELDS OF INTEREST
• The PI has started working on the use of clarithromycin in sepsis since 2002. He has
conducted a series of experimental studies leading to six peer-reviewed publications.
Beneficial results led him to the design and conduct of two prospective, double-blind,
placebo-controlled trials as a sponsor. The trials indicated the subgroups of patients with
sepsis gaining most of benefit from this intervention.
2
Pathogenesis of sepsis with emphasis on immunoparalysis
Innate immunity and biological therapies in hidradenitis suppuarativa
In vitro activities and pharmacokinetic of antimicrobials and their interactions on multidrugresistant species
PUBLISHED WORK
• 192 peer-reviewed published articles in International Scientific Journals; 16 review articles
• 2412 citations; h-index 25
TEACHING EXPERIENCE
• More than 400 hours of undergraduate teaching lectures on infectious diseases and
immunology
• PhD Supervisor of 58 postgraduate students in Athens Medical School; 38 have already
been completed
• 55 times invited speaker in International Meetings
CLINICAL EXPERIENCE
• Supervisor of the Department of Immunology of Infectious Diseases and of
Immunophenotyping of the 4th Department of Internal Medicine, in-patients and outpatients
• Daily consultation in the general wards as internist
SCIENTIFIC AWARDS
• 28 awards in Hellenic Congresses for studies on sepsis
• 7 awards in International Congresses for studies on sepsis
SPECIAL DISTINCTION
• 2009 Young Investigator Research Award of the European Society of Clinical
Microbiology and Infectious Diseases for the contribution in the treatment of sepsis, May
2009, Helsinki, Finland
DESIGN AND CONDUCT OF INVESTIGATOR-INITATED CLINICAL TRIALS AS A
SPONSOR
• June 2004-November 2005 “Immunomodulatory clarithromycin treatment for the
management of ventilator-associated pneumonia and sepsis” (www.clinicaltrials.gov
NCT00297674).
• July 2005-June 2006 “Etenercept for the management of hidradenitis suppurativa”
(EudraCT number 2004-004555-19, www.clinicaltrials.gov NCT00329823).
• July 2007-April 2011 “A double-blind randomized placebo-controlled clinical trial of the
safety and efficacy of intravenous clarithromycin as immunomodulatory therapy for the
management of sepsis” (EudraCT number 2006-004886-33, www.clinicaltrials.gov
NCT01223690).
• January 2009-January 2010 “An open-label non-randomized phase iv trial of the clinical
efficacy of intravenously administered 1000mg paracetamol as antipyretic and analgesic
medication” (EudraCT number 2008-004807-67 www.clinicaltrials.gov NCT01070732)
• May 2006-today: Coordinator of the Hellenic Sepsis Study Group (HSSG, www.sepsis.gr).
HSSG is running research in 65 centers (31 Departments of Internal Medicine; 3
Departments of Pulmonary Medicine; 6 Departments of Surgery; 25 Intensive Care Units)
in Greece and Cyprus through the collection of clinical information and biosamples. Until
today clinical data and samples of DNA/RNA/serum from more than 3500 patients have
been collected. HSSG published guidelines for sepsis in October 2008 and in April 2011.
• April 202-today “A double-blind, randomised, placebo-controlled clinical trial of the safety
and efficacy of anakinra in patients with hidradenitis suppurativa” (EudraCT number 2011005145-12, www.clinicaltrials.gov NCT01558375)
•
•
•
3
LIST OF PUBLICATIONS
Peer-reviewed research articles
1. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Grammatikou M,
Giamarellou H. Do Escherichia coli susceptibilities to various antibiotics decrease in the
presence of polyunsaturated fatty acids? A preliminary report. Journal of
Chemotherapy 1994; 6: 39-43
2. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro activity
and killing effect of DX-8739, a new carbapenem, over meropenem and imipenem
against multiresistant Pseudomonas aeruginosa. Antimicrobial Agents and
3. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro killing
activity of meropenem versus imipenem against multiresistant nosocomial
Pseudomonas aeruginosa. Journal of Chemotherapy 1995; 7: 179-183
4. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. In vitro
inhibitory activity of gamma-linolenic acid on Echerichia coli strains and its influence on
their susceptibilities to various antimicrobial agents. Journal of Antimicrobial
influence of polyunsaturated fatty acids on nosocomial Pseudomonas aeruginosa: A
preliminary report. International Journal of Antimicrobial Agents 1995; 6: 47-50
6. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. In vitro interactions of DX8739, a new carbapenem, meropenem and imipenem with amikacin against
multiresistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1996;
38: 287-291
7. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. Does
the combination of gamma-linolenic acid and arachidonic acid behave in vitro as an
antimicrobial agent? A preliminary report. European Journal of Internal Medicine 1996;
7: 115-118
8. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro
interactions of ceftazidime, meropenem and imipenem with amikacin on multiresistant
Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Diseases 1997; 29:
81-86
9. Giamarellos-Bourboulis EJ, Grecka P, Galani I, Giamarellou H. Comparative in vitro
activity and killing effect of trovafloxacin, DU-6859a, levofloxacin and sparfloxacin
against Staphylococcus aureus. Focus on methicillin-resistant isolates. Clinical Drug
Investigation 1997; 14: 330-336
10. Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H.
In vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial
Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against
methicillin - resistant isolates. Journal of Antimicrobial Chemotherapy 1998; 41: 349355
activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid
peroxidation. Prostaglandins Leukotrienes and Essential Fatty Acids 1998, 58: 283-287
12. Giamarellos-Bourboulis EJ, Pefanis A, Grecka P, Kanellakopoulou K, Giamarellou H.
Interactions of ceftazidime and amikacin on multiresistant Pseudomonas aeruginosa.
Have they altered in the six - year period from 1988 to 1994? Clinical Drug
Investigation 1998; 16: 167-171
13. Giamarellos-Bourboulis EJ, Sambatakou H, Grecka P, Giamarellou H. In vitro activity
of quinupristin/dalfopristin and newer quinolones combined with gentamicin against
4
resistant isolates of Enterococcus faecalis and Enterococcus faecium. European
Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 657-661
14. Giamarellos-Bourboulis EJ, Perdios J, Lelekis M, Eoconomou E, Tsouroulas P,
Giamarellou H. Impact of cefuroxime administration on endotoxin (LPS) and tumour
necrosis factor-a (TNFa) blood levels in patients suffering from acute pyelonephrits: a
preliminary report. International Journal of Antimicrobial Agents 1999; 11: 115-119
15. Kanellakopoulou K, Kolia M, Anastassiadis A, Korakis T, Giamarellos-Bourboulis EJ,
Andreopoulos A, Dounis E, Giamarellou H. Lactic acid polymers as biodegradable
carriers of fluoroquinolones: an in vitro study. Antimicrobial Agents and Chemotherapy
1999; 43: 714-716
16. Giamarellos-Bourboulis EJ, Sambatakou H, Grecka P, Chryssouli Z, Giamarellou H.
Sitafloxacin (DU-6859a) and trovafloxacin: Postantibiotic effect and in vitro interactions
with rifampin on methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology
and Infectious Diseases 1999;, 34: 301-307
17. Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, Tympanidou C, Giamarellou H. In
vitro activity of FK 037 (cefoselis), a novel 4th generation cephalosporin, compared to
cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
Diagnostic Microbiology and Infectious Diseases 2000; 36: 185-191
18. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. Impact
of n-6 polyunsaturated fatty acids on growth of multiresistant Pseudomonas
aeruginosa. Interactions with amikacin and ceftazidime. Antimicrobial Agents and
Chemotherapy 2000; 44: 2187-2189
19. Kanellakopoulou K, Galanakis N, Giamarellos-Bourboulis EJ, Rifiotis Ch, Papakostas
K, Andreopoulos A, Dounis E, Karagianakos P, Giamarellou H. Treatment of
experimental osteomyelitis by methicillin-resistant Staphylococcus aureus with a
biodegradable system of lactic acid releasing pefloxacin. Journal of Antimicrobial
20. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panou C, Adamakis I,
Giamarellou H. Pharmacokinetics of clarithromycin in the prostate: implications for the
treatment of chronic abacterial prostatitis. Journal of Urology 2001; 165: 97-99
21. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Stinios I, Chrisifos M,
Giannopoulou M, Giamarellou H. Pharmacokinetics of intravenously administered
pefloxacin in the prostate: perspectives for its application in surgical prophylaxis.
International Journal of Antimicrobial Agents 2001; 17: 221-224
22. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, Endtz HP, van
der Braak N, Fernandes CJ, Fernandes L, Frimondt-Moller N, Rasmussen LS,
Giamarellou H, Giamarellos-Bourboulis E, Jarlier V, Nguyen J, Nord CE, Struelens
MJ, Nonhoff C, Turnidge J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL. In vitro
activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe
and Australia. Antimicrobial Agents and Chemotherapy 2001; 45: 1860-1867
23. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N,
Giamarellou H. Assesment of procalcitonin as a diagnostic marker of underlying
infection in patients with febrile neutropenia. Clinical Infectious Diseases 2001; 32:
1718-1728
24. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and
rifampin on multidrug-resistant Acinetobacter baumannii. Diagnostic Microbiology and
Infectious Diseases 2001, 40: 117-120
25. Sambatakou H, Giamarellos-Bourboulis EJ, Galanakis N, Giamarellou H.
Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of
penetration in the ascitic fluid. International Journal of Antimicrobial Agents 2001; 18:
441-444
5
26. Giannopoulos A, Giamarellos-Bourboulis EJ, Adamakis I, Georgopoulou I, Petrikkos
G, Katsilambros N. Epididymitis caused by Candida glabrata. A novel infection in
diabetic patients? Diabetes Care 2001; 24: 2003-2004
27. Nikou GC, Arnaoutis Th, Giamarellos-Bourboulis EJ, Samolada O, VafiadisZouboulis I, Katsilambros N, Arvanitakis C. The significance of the dosage adjustment
of octreotide in the treatment of acute pancreatitis of moderate severity.
Hepatogastrenterology 2001; 48: 1754-1757
28. Papaioannou MG, Marinaki S, Pappas M, Stamatiadis D, Giamarellos-Bourboulis EJ,
Giamarellou H, Stathakis Ch. Pharmacokinetics of teicoplanin in patients undergoing
chronic haemodialysis. International Journal of Antimicrobial Agents 2002; 19: 233-236
29. Nikou GC, Giamarellos-Bourboulis EJ, Toumpanakis Ch, Arnaoutis TP, Kitsou E,
Kyriaki D, Katsilambros N. Changes of plasma levels of gastrointestinal peptides over
the course of acute pancreatitis. Any significance for the pathophysiology and
treatment of acute pancreatitis? Hepatogastroenterology 2002; 19: 706-708
30. Giamarellos-Bourboulis EJ, Grecka P, Petrikkos GL, Toskas A, Katsilambros N.
Primary meningococcal arthritis: case report and review. Clinical and Experimental
Rheumatology 2002; 20: 553-554
31. Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G,
Thomopoulos G, Giamarellou H. Procalcitonin: a marker to clearly differentiate
systemic inflammatory response syndrome and sepsis in the critically ill patient?
Intensive Care Medicine 2002; 28: 1351-1356
32. Giamarellos-Bourboulis EJ, Karnessis L, Galani I, Giamarellou H. In vitro killing effect
of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to
trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy 2002; 46:
3997-3999
33. Giamarellos-Bourboulis EJ, Skiathitis S, Dionyssiou-Asteriou A, Donta I,
Hatziantoniou S, Demetzos K, Papaioannou GT, Karatzas G, Giamarellou H. Rapid
alterations of serum oxidant and antioxidant status with the intravenous administration
of n-6 polyunsaturated fatty acids. Prostaglandins Leukotrienes and Essential Fatty
Acids 2002; 67: 57-62
34. Koratzanis G, Giamarellos-Bourboulis EJ, Papalambros E, Giamarellou H. Bacterial
translocation following intrabdominal surgery. Any influence of antimicrobial propylaxis?
35. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with
rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas
maltophilia. Diagnostic Microbiology and Infectious Disease 2002; 44: 259-263
36. Giamarellos-Bourboulis EJ, Plachouras D, Skiathitis S, Raftogiannis M, DionyssiouAsteriou A, Dontas I, Karayannacos PE, Giamarellou H. Ex vivo synergy of
arachidonate enriched serum with ceftazidime and amikacin on multidrug-resistant
Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 2003; 51: 423-426
37. Giamarellos-Bourboulis EJ, Tzivras M, Kourtesas D, Arnaoutis TP, Delladetsima I,
Dionyssiou-Asteriou A, Davaris P, Vafiadis-Zouboulis I, Archimandritis A. Lipid
peroxidation in chronic gastritis: any influence of Helicobacter pylori? Prostaglandins
Leukotrienes and Essential Fatty Acids 2003; 68: 257-261
38. Stamatiadis D, Papaioannou MG, Giamarellos-Bourboulis EJ, Marinaki S,
Giamarellou H, Stathakis CP. Pharmacokinetics of teicoplanin in patients undergoing
continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 2003; 23:
127-131
39. Papagoras D, Giamarellos-Bourboulis EJ, Kanara M, Douridas G, Paraskevopoulos
I, Antzaklis G, Karayannacos PE, Giamarellou H. Pancreatic concentrations of
cefepime in experimental necrotizing pancreatitis. Journal of Chemotherapy 2003; 15:
43-46
6
40. Elezoglou AV, Giamarelos-Bourboulis E, Katsilambros N, Sfikakis PP. Cutaneous
vasculitis associated with mixed cryoglobulinemia in adult Still’s disease. Clinical and
Experimental Rheumatology 2003; 21: 405-406
41. Giamarellos-Bourboulis EJ, Nikou GC, Petrikkos GL, Mouktaroudi M, Toskas A,
Katsilambros N. Pneumocystis carinnii pneumonia in an immunocompetent host.
Clinical Drug Investigation 2003; 23: 135-137
42. Giamarellos-Bourboulis EJ, Skiathitis S, Dionyssiou-Asteriou A, Hatziantoniou S,
Demetzos K, Dontas I, Papaioannou GT, Karatzas K, Giamarellou H. Lipid peroxidation
by Pseudomonas aeruginosa in the pathogenesis of nosocomial sepsis. Journal of
Postgraduate Medicine 2003; 49: 11-16
43. Giamarellos-Bourboulis EJ, Perdios J, Gargalianos P, Kosmidis J, Giamarellou H.
Antimicrobial-induced endotoxemia in patients with sepsis in the field of acute
pyelonephritis. Journal of Postgraduate Medicine 2003; 49: 118-122
44. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro
interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.
Journal of Chemotherapy 2003; 15: 235-238
45. Giamarellos-Bourboulis EJ, Nikou GC, Matsaggoura M, Toumpanakis C, Grecka P,
Giannikopoulos G, Katsilambros N. Alterations of systemic endotoxaemia over the
course of acute oedematous pancreatitis. Correlation to the advent of an infection?
Pancreatology 2003; 3: 323-328
46. Giamarellos-Bourboulis EJ, Poulaki H, Kostomitsopoulos N, Dontas I, Perrea D,
Karayannacos PE, Giamarellou H. Effective immunomodulatory treatment of
Escherichia coli experimental sepsis with thalidomide. Antimicrobial Agents and
Chemotherapy 2003; 47: 2445-2449
47. Koutelidakis I, Papaziogas B, Giamarellos-Bourboulis EJ, Makris J, Pavlidis T,
Giamarellou H, Papaziogas T. Systemic endotoxaemia following obstructive jaundice:
the role of lactulose. Journal of Surgical Research 2003; 113: 243-247
48. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V,
Mouktaroudi M, Perrea D, Karayannacos P, Giamarellou H. Immunomodulatory
clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by
multidrug-resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy
2004; 48: 93-99
49. Giamarellos-Bourboulis EJ, Plachouras D, Tzivra A, Koussoulas V, Bolanos N,
Raftogiannis M, Galani I, Dontas I, Dionyssiou-Asteriou A, Giamarellou H. Stimulation
of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa:
an in vitro and in vivo study. Clinical and Experimental Immunology 2004; 135: 240-246
50. Adamis G, Papaioannou MG, Giamarellos-Bourboulis EJ, Gargalianos P, Kosmidis
J, Giamarellou H. Pharmacokinetic interactions of ceftazidime, imipenem and
aztreonam with amikacin in healthy volunteers. International Journal of Antimicrobial
Agents 2004; 23: 144-149
51. Hatziantoniou S, Giamarellos-Bourboulis EJ, Skiathitis S, Demetzos C, Donta I,
Papaioannou GT, Dionyssiou-Asteriou A, Karayannacos PE, Giamarellou H. Rapid
alterations of serum fatty acids with the intravenous administration of an arachidonate
solution. Prostaglandins Leukotrienes and Essential Fatty Acids 2004; 70: 465-468
52. Dontas I, Sokolis DP, Giamarellos-Bourboulis EJ, Tzonou A, Giamarellou H,
Karayannacos PE. The influence of indomethacin co-administration on ofloxacin levels
in plasma and cerebrospinal fluid in rats. International Journal of Antimicrobial Agents
2004; 23: 371-376
53. Nikou GC, Giamarellos-Bourboulis EJ, Grecka P, Toumpanakis Ch, Giannikopoulos
G, Katsilambros N. Effect of octreotide administration on serum interleukin-6 levels of
patients with acute oedematous pancreatitis. Hepatogastroenterology 2004; 51: 599602
7
54. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos
N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krçmery V,
Menichetti F, Panaretou E, Papageorgiou E, Plachouras D. Potential use of
procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a
multicentre study. Clinical Microbiology and Infection 2004; 10: 628-633
55. Lazarettos J, Efstathopoulos N, Papagelopoulos PJ, Savvidou O, Kanellakopoulou K,
Giamarellou H, Giamarellos-Bourboulis EJ, Nikolaou V, Kapranou A, Papalois,
Papachristou G. A bioresorbable calcium phosphate delivery system with teicoplanin
for treating MRSA osteomyelitis. Clinical Orthopaedics and Related Research 2004;
423: 253-258
56. Papaziogas B, Koutelidakis IM, Giamarellos-Bourboulis EJ, Lazaridis Ch, Kousoulas
V, Galanis I, Giamarellou H, Atmatzidis K. Lipid peroxidation and inguinal hernia repair.
Tension-free vs. Andrews technique. Prostaglandins Leukotrienes and Essential Fatty
Acids 2004; 71: 221-225
57. Petropoulou H, Giamarellos-Bourboulis EJ, Kavatzas N, Stratigos A, Mouktaroudi M,
Adamis T, Baziaka F, Katsambas AD, Stravrianeas NG. Early cutaneous alterations in
experimental sepsis by Pseudomonas aeruginosa. Dermatology 2004; 209: 111-116
58. Giamarellos-Bourboulis EJ, Koussoulas V, Panagou C, Adamis T, Baziaka F,
Skiadas I, Perrea D, Dionyssiou-Asteriou A, Giamarellou H. Experimental sepsis using
Pseudomonas aeruginosa: the significance of multi-drug resistance. International
Journal of Antimicrobial Agents 2004; 24: 357-361
59. Giamarellos-Bourboulis EJ, Giannopoulou P, Grecka P, Voros D, Mandragos K,
Giamarellou H. Should procalcitonin be introduced in the diagnostic criteria of the
systemic inflammatory response syndrome and sepsis? Journal of Critical Care 2004;
19: 152-157
60. Giamarellos-Bourboulis EJ, Mouktaroudi M, Adamis T, Koussoulas V, Baziaka F,
Perrea D, Karayannacos PE, Giamarellou H. n-6 polyunsaturated fatty acids enhance
the activities of ceftazidime and amikacin in experimental sepsis caused by mulridrugresistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2004; 48:
4713-4717
61. Koussoulas V, Giamarellos-Bourboulis EJ, Adamis T, Mouktaroudi M, Sabracos L,
Perrea D, Giamarellou H, Dionyssiou-Asteriou A. The significance of
oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrugresistant Pseudomonas aeruginosa. Prostaglandins Leukotrienes and Essential Fatty
Acids 2005; 72: 41-47
62. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, Koutoukas P, Kousoulas V,
Sabracos L, Panagou C, Perrea D, Giamarellou H. Clarithromycin co-administered with
amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli.
63. Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, Plachouras D,
Tsaganos T, Giamarellou H. Postantibiotic effect of antimicrobial combinations on
multidrug-resistant Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious
Disease 2005; 51: 113-117
64. Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, Raftogiannis M, Baziaka T,
Tsaganos T, Koutoukas P, Plachouras D, Karayannacos P, Giamarellou H.
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute
pyelonephritis by Escherichia coli. Scandinavian Journal of Infectious Diseases 2005;
37: 48-54
65. Efstathopoulos N, Bathrellos E, Giamarellos-Bourboulis EJ, Lazarettos J, Papalois A,
Grecka P, Vassiliou V. N-6 polyunsaturated fatty acids confer hemodynamic stability in
an experimental model of multiple trauma. Prostaglandins Leukotrienes and Essential
Fatty Acids 2005; 72: 357-362
8
66. Liapakis IE, Light RW, Pitiakoudis MS, Karayiannakis AJ, Giamarellos-Bourboulis
EJ, Ismailos G, Anagnostoulis S, Simopoulos CE, Bouros DE. Penetration of
clarithromycin in an experimental model of empyema. Respiration 2005; 72: 296-300
67. Giamarellos-Bourboulis EJ, Bolanos N, Laoutaris G, Papadakis V, Koussoulas V,
Perrea D, Karayannacos P, Giamarellou H. Immunomodulatory intervention in sepsis
by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental
study. BMC Infectious Diseases 2005; 5: 51
68. Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S,
Koronaios A, Zakynthinos S, Armaganidis A, Giamarellou H, Roussos C. Does soluble
triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of
septic shock? Clinical and Experimental Immunology 2005; 142: 62-67
69. Giamarellos-Bourboulis EJ, Ζakynthinos S, Baziaka F, Papadomichelakis E, Virtzili
S, Koutoukas P, Armaganidis A, Giamarellou H, Roussos C. Soluble triggering receptor
expressed on myeloid cells-1 as an antiinflammatory mediator in sepsis. Intensive Care
Medicine 2006; 32: 237-243
70. Plachouras D, Stamatakos M, Baziaka F, Giamarellos-Bourboulis EJ, Tsaganos T,
Giamarellou H, Safioleas M. Portal and systemic endotoxemia in abdominal operations:
the significance of acute abdomen. Journal of Surgical Research 2006; 134: 133-137
71. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P,
Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H. Clarithromycin is an
effective immunomodulator when administered late in experimental pyelonephritis by
multidrug-resistant Pseudomonas aeruginosa. BMC Infectious Diseases 2006; 6: 31
72. Koussoulas V, Vassiliou S, Demonakou M, Giamarellos-Bourboulis EJ, Tassias G,
Mouktaroudi M, Giamarellou H, Barbatzas C. Soluble triggering receptor expressed on
myeloid cells (sTREM-1): A new mediator involved in the pathogenesis of peptic ulcer
disease. European Journal of Gastroenterology and Hepatology 2006; 18: 375-379
76. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Antonopoulou A,
Adamis T, Sabracos L, Giamarellou H. Clarithromycin is an effective immunomodulator
in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. Journal
of Antimicrobial Chemotherapy 2006; 57: 937-944
77. Giamarellos-Bourboulis EJ, Routsi C, Plachouras D, Markaki V, Raftogiannis M,
Zervakis D, Koussoulas V, Orfanos S, Kotanidou A, Armaganidis A, Roussos C,
Giamarellou H. Early apoptosis of blood monocytes in the septic host: is it a
mechanism of protection in the event of septic shock? Critical Care 2006; 10: R76
78. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T,
Koutoukas P, Giamarellou H, Archimandritis A. Role of soluble triggering receptor
expressed on myeloid cells in inflammatory bowel disease. World Journal of
Gastroenterology 2006; 12: 3416-3419
79. Efstathopoulos N, Tsaganos N, Giamarellos-Bourboulis EJ, Kaldis P, Nicolaou V,
Papalois A, Koutoukas P, Papachristou G, Giamarellou H. Early apoptosis of
monocytes contributes to the pathogenesis of systemic inflammatory response and of
bacterial translocation in an experimental model of multiple trauma. Clinical and
Experimental Immunology 2006; 145: 139-146
80. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A,
Tsaganos T, Kanellakopoulou K, Giamarellou H. Multidrug-resistance to antimicrobials
as a predominant factor influencing patient survival. International Journal of
Antimicrobial Agents 2006; 27: 476-481
81. Giamarellos-Bourboulis EJ, Geladopoulos T, Chrisofos M, Koutoukas P, Vassiliadis
J, Alexandrou I, Tsaganos T, Sabracos L, Karagianni V, Pelakanou E, Tzepi I,
Kranidioti H, Koussoulas V, Giamarellou H. Oleuropein: a novel immunomodulator
conferring prolonged survival in experimental sepsis by multidrug-resistant
Pseudomonas aeruginosa. Shock 2006; 26: 410-416
9
82. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis
E. Benefits of a symbiotic formula (Symbiotic 2000Forte) in critically ill trauma patients:
results of a randomized controlled trial. World Journal of Surgery 2006; 30: 1848-1855
83. Plachouras D, Routsi C, Giamarellos-Bourboulis EJ, Spyridaki E, Andrianakis I,
Metzelopoulos S, Tsaganos T, Floros I, Douzinas EE, Armaganidis A, Roussos C,
Giamarellou H. Monocytes as a site of production of soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1) in the septic host. Scandinavian Journal of
Infectious Diseases 2006; 38: 909-915
84. Tsaganos T, Giamarellos-Bourboulis EJ, Kollias S, Zervakis D, Karagianni V,
Pelekanou A, Tampaki AC, Kontogiorgi M, Koroneos A, Drakoulis N, Armaganidis A,
Roussos C, Giamarellou H. Kinetics of progenitor hemopoetic stem cells in sepsis.
Correlation with patients’ survival? BMC Infectious Diseases 2006; 6: 142
85. Douzinas EE, Livaditi O, Xiarchos A, Giamarellos-Bourboulis EJ, Villiotou V, Liappas
IA, Evangelou E, Rapidis AD, Roussos C. The effect of hypoxemic resuscitation of
hemorrhagic shock on hemodynamic stabilization and inflammatory response: a pilot
study in a rat experimental model. Journal of Trauma 2006; 61: 918-923
86. Koussoulas V, Tzivras M, Karagianni V, Spyridaki E, Plachouras D, Giamarellou H,
Giamarellos-Bourboulis EJ. Monocytes in systematic inflammatory response
syndrome: differences between sepsis and acute pancreatitis. World Journal of
Gastroenterology 2006; 12: 6711-6714
87. Giamarellos-Bourboulis EJ, Mega A, Pavleas I, Archontoulis N, Rigas K, Vernikos P,
Giamarellou H, Thomopoulos G. Impact of carbapenem administration on systemic
endotoxemia in patients with severe sepsis and Gram-negative bacteremia. Journal of
88. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D,
Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H. Early changes of CD4positive lymphocytes and NK cells in patients with severe Gram-negative sepsis.
Critical Care 2006; 10: R166
89. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V,
Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant
Acinetobacter baumannii. Diagnostic Microbiology and Infectious Diseases 2007; 57:
419-422
90. Pantopoulou A, Giamarellos-Bourboulis EJ, Ragtogiannis M, Tsaganos T, Donta I,
Koutoukas P, Baziaka F, Giamarellou H, Perrea D. Colistin offers prolonged survival in
experimental infection by multidrug-resistant Acinetobacter baumannii: the significance
of co-administration of rifampicin. International Journal of Antimicrobial Agents 2007;
29: 51-55
91. Giamarellos-Bourboulis EJ, Antonopoulou A, C. Petropoulou, Mouktaroudi M,
Spyridaki M, Baziaka F, Pelekanou M, Giamarellou H, Stavrianeas NG. Altered innate
and adaptive immune response in patients with hidradenitis suppurativa. British Journal
of Dermatology 2007; 156: 51-56
92. Koussoulas V, Tzivras M, Giamarellos-Bourboulis EJ, Demonakou M, Vassilliou S,
Pelekanou A, Papadopoulos A, Giamarellou H, Barbatzas C. Can soluble triggering
receptor expressed on myeloid cells (sTREM-1) be considered as an anti-inflammatory
mediator in the pathogenesis of peptic ulcer disease? Digestive Diseases and
Sciences 2007; 52: 2166-2169
93. Dimopoulou I, Armaganidis A, Douka E, Mavrou I, Augustatou C, Kopterides P,
Lyberopoulos P, Tzanella M, Orfanos SE, Pelekanou E, Kostopanagiotou G, Macheras
A, Giamarellos-Bourboulis EJ. Tumour necrosis factor-alpha (TNFα) and interleukin10 are crucial mediators in post-operative systemic inflammatory response and
determine the occurrence of complications after major abdominal surgery. Cytokine
2007; 37: 55-61
10
94. Alexiou Z, Mouktaroudi M, Koratzanis G, Papadopoulos S, Kavatha D,
Kanellakopoulou K, Giamarellou H, Giamarellos-Bourboulis EJ. The significance of
compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract
infections: the Greek experience. International Journal of Antimicrobial Agents 2007;
30: 40-43
95. Antonopoulou A, Raftogiannis M, Giamarellos-Bourboulis EJ, Koutoukas P,
Sabracos L, Mouktaroudi M, Adamis T, Tzepi I, Giamarellou H, Douzinas EE. Early
apoptosis of blood monocytes is a determinant of survival in experimental sepsis by
multi-drug-resistant Pseudomonas aeruginosa. Clinical and Experimental Immunology
2007; 149: 103-108
96. Mentzelopoulos S, Pratikaki M, Platsouka E, Kraniotaki E, Zervakis D, Koutsoukou A,
Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis EJ, Routsi C, Zakynthinos
SG. Prolonged use of carbapenems and colistin predisposes to ventilator-associated
pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Medicine
2007; 33: 1524-1532
97. Koussoulas V, Vassiliou S, Spyridaki E, Demonakou M, Vaki I, Barbatzas C,
Giamarellou H, Giamarellos-Bourboulis EJ. Evidence for the role of gastric mucosa
at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in
peptic ulcer disease. World Journal of Gastroenterology 2007; 13: 4610-4614
98. Livaditi O, Giamarellos-Bourboulis EJ, Kakkas I, Kaspimali V, Lymberi P,
Papasteriades C, Douzinas E. Grouping of patients with common variable
immunodeficiency based on immunoglobulin biosynthesis: comparison with a
classification system on CD4-naïve cells. Immunology Letters 2007; 114, 103-109
99. Douzinas EE, Livaditi O, Tasoulis MK, Pelekanou A, Giamarellos-Bourboulis EJ.
Stimulation of monocytes is a pathway involved in systemic inflammatory response
following haemorrhagic shock resuscitation: the effect of hypoxaemic resuscitation.
Clinical and Experimental Immunology 2007; 150: 502-508
100. Ferwerda B, McCall MBB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M,
Izagirre N, Syafruddin D, Cristea T, Hijmans A, Hamann L, Israel J, ElGhazali G,
Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Hermsen CC, Stalenhoef
AFH, van Crevel R, Brunner HG, Oh DY, Schumann RR, de la Rua C, Sauerwein R,
Kullberg BJ, van der Ven AJAM, van der Meer JWM, Netea MG. TLR4 polymorphisms,
infectious diseases, and evolutionary pressure during migration of modern humans.
Proceedings of the National Academy of Sciences of USA 2007; 104: 16645-16650
101. Karapanagiotou EM, Pelekanou E, Charpidou A, Tsaganos T, Anagnostou V,
Plachouras D, Giamarellos-Bourboulis EJ, Syringos KN. Soluble triggering receptor
expressed on myeloid cells-1 detection in cancer patient: a prognostic marker for lung
metastases from solid malignancies. Anticancer Research 2008; 28: 1411-1416
102. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H,
Baziaka F, Pelekanou M, Karagianni V, Stavrianeas NG, Giamarellou H. An open-label
phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis
suppurativa. British Journal of Dermatology 2008; 158: 567-572
103. Chatzimavroudis G, Koutelidakis I, Papaziogas B, Tsaganos T, Koutoukas P,
Giamarellos-Bourboulis E, Atmatzidis S, Atmatzidis K. The effect of the type of
intraperitoneally implanted prosthetic mesh on the systemic inflammatory response.
Hernia 2008; 12: 277-283
104. Bristianou M, Panagou C, Adamis T, Raftoagiannis M, Antonopoulou A, Chrisofos
M, Galani I, Kanellakopoulou K, Tsaganos T, Giamarellos-Bourboulis EJ. The impact
of multidrug-resistance on the pathogenicity of Escherichia coli: an experimental study.
105. Papathanassiou M, Throdossiadis PG, Liarakos VS, Rouvas A, GiamarellosBourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjuctival
11
becavizumab in an animal model. Americal Journal of Ophthalmology 2008; 145: 424431
106. Dimopoulou I, Orfanos S, Kotanidou A, Livaditi O, Giamarellos-Bourboulis EJ,
Athanasiou C, Korovesi I, Sotiropoulou C, Kopterides P, Kanellakopoulou K,
Armaganidis A. Plasma pro- and anti-inflammatory cytokine levels and outcome
prediction in unselected critically ill patients. Cytokine 2008; 41: 263-267
107. Kyriakopoulou K, Antonopoulou A, Raftogiannis M, Baziaka F, Tsaganos T,
Kanellakopoulou K, Giamarellos-Bourboulis EJ. The importance of fever as a
predictive symptom of host’s monocytes to release pro- and anti-inflammatory
mediators. Mediators of Infammation 2008; 450196
108. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, Plachouras D, Kollias S,
Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V,
Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas A,
Kotanidou A, Roussos A, Giamarellou H. Effect of clarithromycin in patients with sepsis
and ventilator-associated pneumonia. Clinical Infectious Diseases 2008; 46: 1157-1164
109. Baziaka F, Giamarellos-Bourboulis EJ, Raftogiannis M, Adamis T, Tziortzioti V,
Sabracos L, Chrisofos M, Koutoukas P, Giamarellou H, Douzinas EE.
Immunomodulatory effect of three-day continuous administration of clarithromycin for
experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa. Journal of
110. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, Vafiadou M, Kranidioti H,
Giamarellou H, Giamarellos-Bourboulis EJ. Pharmacokinetics of moxifloxacin in noninflamed cerebrospinal fluid of humans: implication for a bactericidal effect. Journal of
Antimicrobial Chemotherapy 2008; 61: 1328-1331
111. Tsaganos T, Kouki P, Digenis P, Giamarelou H, Giamarellos-Bourboulis EJ,
Kanellakopoulou K. Pharmacokinetics of levofloxacin after single and multiple oral
doses in patients undergoing inermittent haemodialysis. International Journal of
112. Kanellakopoulou K, Sarafis P, Galani I, Giamarellou H, Giamarellos-Bourboulis
EJ. In vitro synergism of β-lactams with ciprofloxacin and moxifloxacin against
genetically multidrug-resistant isolates of Pseudomonas aeruginosa. International
Journal of Antimicrobial Agents 2008; 61: 33-39
113. Kanellakopoulou K, Thivaios GC, Kolia M, Dontas I, Nakopoulou L, Dounis E,
Giamarellos-Bourboulis EJ, Andreopoulos A, Karagiannakos P, Giamarellou H.
Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a
biodegradable dilactide polymer releasing ciprofloxacin. Antimicrobial Agents and
Chemotherapy 2008; 52: 2335-2339
114. Tsaganos T, Skiadas I, Koutoukas P, Adamis T, Baxevanos N, Tzepi I, Pelekanou
A, Giamarellos-Bourboulis EJ, Giamarellou H, Kanellakoupoulou K. Efficacy and
pharmacodynamics of linezolid, alone and in combination with rifampicin, in an
experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
Journal of Antimicrobial Chemotherapy 2008; 62: 381-383
115. Douzinas EE, Andrianakis I, Livaditi O, Panelis P, Tasoulias M, Pelekanou A,
Betrosian A, Giamarellos-Bourboulis EJ.
The level of hypotension during
hemorrhagic shock is a major determinant of the post-resuscitation systemic
inflammatory response: an experimental study. BMC Physiology 2008; 8: 15
113. Kanellakopoulou K, Tselikos D, Giannitsioti E, Giamarellos-Bourboulis EJ,
Apostolakis E, Lolas C, Giamarellou H. Pharmacokinetics of cefepime and fusidic acid
in heart tissues: implications for a role in surgical prophylaxis. Journal of Chemotherapy
2008; 20: 468-471
114. Pavleas J, Skiada A, Daikos GL, Pefanis A, Giamarellos-Bourboulis E,
Kanellakopoulou K, Tsaganos T, Perrea D, Donta I, Karayannakos P, Giamarellou H.
12
Efficacy of teicoplanin, administered in two different regimens, in the treatment of
experimental endocarditis due to Enterococcus faecalis. Journal of Chemotherapy
2008; 20: 208-212
115. Giamarellos-Bourboulis EJ, Kanellakopoulou K, Pelekanou A, Tsaganos T,
Kotzampassi K. Kinetics of angiopoietin-2 in serum of multi-trauma patients: correlation
with patient severity. Cytokine 2008; 44: 310-313
116. Kanellakopoulou K, Sahinides T, Tsaganos T, Galanakis N, Giamarellou H,
Giamarellos-Bourboulis EJ. In vitro release of tecicoplanin and fusidic acid from
cancellous bone allografts. Journal of Chemotherapy 2008; 20: 645-647
117. Efstathopoulos N, Giamarellos-Bourboulis E, Kanellakopoulou K, Lazarettos I,
Giannoudis P, Frangia K, Magnissalis E, Papadaki M, Nikolaou VS. Treatment of
experimental osteomyelitis by methicillin-resistant Staphylococcus aureus with bone
cement system releasing grepafloxacin. Injury 2008; 39: 1384-1390
118. Giamarellos-Bourboulis EJ, Mouktaroudi M, Tsaganos T, Koutoukas P, Spyridaki
E, Pelekanou A, Kotzampassi K. Evidence for the participation of soluble triggering
receptor expressed on myeloid cells-1 in the systemic inflammatory response
syndrome after multiple trauma. Journal of Trauma 2008; 65: 1385-1390
119. Tzepi I, Vergados I, Kanellakopoulou K, Papathanassiou M, Kranidioti H, Tsaganos
T, Liarakos V, Giamarellos-Bourboulis EJ, Theodossiadis P. Pharmacokinetics of
intravenously administered moxifloxacin in eye compartments: an experimental study.
120. Kopterides P, Kapetanakis T, Siempos II, Magkou C, Pelekanou E, Tsaganos T,
Giamarellos-Bourboulis EJ, Roussos C, Armaganidis A. Short-term administration of
a high-oxygen concentration is not injurious in an ex-vivo rabbit model of ventilatorinduced acute lung injury. Anesthesia and Anelgesia 2009; 108: 556-564
121. Giamarellos-Bourboulis EJ, Douzinas EE, Tsaganos T, Pagoulatou A, Livaditi O,
Vafiadou M, Kanellakopoulou K. Cerebrospinal fluid of patients administered
moxifloxacin modulates the secretion of cytokines from human monocytes. Diagnostic
Microbiology and Infectious Disease 2009; 63: 62-69
122. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J, Kullberg BJ,
Netea M, van der Meer JMW. Crystals of monosodium urate monohydrate enhance
lipopolysaccharide-induced release of interleukin-1β through a caspase-1 mediated
process. Annals of the Rheumatic Diseases 2009; 68: 273-278
123. Chatzimavroudis G, Pavlidis TE, Koutelidakis I, Giamarrelos-Bourboulis EJ,
Atmatzidis S, Kontopoulou K, Marakis G, Atmatzidis K. CO2 pneumoperitoneum
prolongs survival in an animal model of peritonitis compared to laparotomy. Journal of
Surgical Research 2009; 152: 69-75
124. Kanellakopoulou K, Galanopoulos I, Soranoglou V, Tsaganos T, Tziortzioti V, Maris
I, Giamarellou H, Giamarellos-Bourboulis EJ. Treatment of experimental
osteomyelitis by methicillin-resistant Staphylococcus aureus with a synthetic carrier of
calcium sulphate (Stimulan) releasing moxifloxacin. International Journal of
125. Koussoulas V, Vassiliou S, Giamarellos-Bourboulis EJ, Tassias G, Kotsaki A,
Barbatzas C, Tzivras M. Implications for the role of interleukin-23 in the pathogenesis
of chronic gastritis and of peptic ulcer disease. Clinical and Experimental Immunology
2009; 156: 97-101
126. Kanellakopoulou K, Papadopoulos A, Varvaroussis D, Varvaroussis A,
Giamarellos-Bourboulis EJ, Pagonas A, Stergiou A, Papadelis P, Nikolaidis N,
Giamarellou H. Efficacy of teicoplanin for the prevention of surgical site infections after
total hip or knee arthroplasty: a prospective, open-label study. International Journal of
13
127. Kanellakopoulou K, Giannitsioti E, Papadopoulos A, Athanassia A, GiamarellosBourboulis EJ, Giamarellou H. Chronic bone infections due to Enterobacter cloacae:
current therapeutic trends and clinical outcome. Journal of Chemotherapy 2009; 21:
226-228
128. Dimopoulou I, Orfanos SE, Pelekanou A, Kotanidou A, Livaditi O, Augustatou C,
Zervou M, Douka E, Theodorakopoulou M, Karagianni V, Douzinas E, Armaganidis A,
Giamarellos-Bourboulis EJ. Serum of patients with septic shock stimulates the
expression of TREM-1 on U937 monocytes. Inflammation Research 2009; 57: 1-6
129. Lazaris AM, Maheras AN, Vasdekis SN, Karkaletsis KG, Charalambopoulos A,
Kakisis JD, Martikos G, Patapis P, Giamarellos-Bourboulis EJ, Karatas GM,
Liakakos TD. Protective effect of remote ischemic preconditioning in renal
ischemia/reperfusion injury, in a model of thoracoabdominal aorta approach. Journal of
Surgical Research 2009; 154: 267-273
130. Kanellakopoulou K, Panagopoulos P, Giannitsioti E, Tsaganos T, Carrer DP,
Efstathopoulos N, Giamarellos-Bourboulis EJ. In vitro elution of daptomycin by a
synthetic crystallic form of calcium sulftate, Stimulan. Antimicrobial Agents and
Chemotherapy 2009; 53: 3106-3107
131. Ferwerda B, Alonso S, Banahan K, McCall MBB, Giamarellos-Bourboulis EJ,
Ramakers BP, Mouktaroudi M, Fain PR, Izagirre N, Syafruddin D, Cristea T,
Mockenhaupt FP, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O,
Sundaresan S, Bedu-Addo G, van Crevel R, Hamman L, Oh DY, Schumann RR,
Joosten LAB, de la Rua C, Sauerwein R, Drenth JPH, Kullberg BJ, van der Ven AJAM,
Hill AV, Pickkers P, van der Meer JWM, O’Neil LAJ, Netea MG. Functional and genetic
evidence that the Mal/TIRAP allele variant 180L as been selected by providing
protection against septic shock. Proceedings of the National Academy of Sciences of
USA 2009; 106: 10272-10277
132. Kranidioti H, Orfanos SE, Vaki I, Kotanidou A, Raftogiannis M, Dimopoulou I,
Kotsaki A, Savva A, Papapetropoulos A, Armaganidis A, Giamarellos-Bourboulis EJ.
Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating
factor stimulating its release from human monocytes. Immunology Letters 2009; 125:
65-71
133. Douzinas EE, Betrosian A, Livaditi I, Flevari A, Kanni T, Mouktaroudi M,
Giamarellos-Bourboulis EJ. Hypoxemic resusciatation after hemorrhagic shock is
accompanied by reduced serum levels of angiopoietin-2. Cytokine 2009; 47: 82-84
134. Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K.
Pro- and synbiotics to control inflammation and infection in patients with multiple
injuries. Journal of Trauma 2009; 67: 815-821
135. Pelekanou A, Tsangaris I, Kotsaki A, Karagianni V, Giamarellou H, Armaganidis A,
Giamarellos-Bourboulis EJ. Decrease of CD4-lymphocytes and apoptosis of CD14monocytes are characteristic alterations in sepsis caused by ventilator-associated
pneumonia: results from an observational study. Critical Care 2009; 13: R172
136. Skalioti C, Tsaganos T, Stamatiadis D, Giamarellos-Bourboulis EJ, Boletis J,
Kanellakopoulou K. Pharmacokinetics of moxifloxacin in patients undergoing
continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 2009; 29:
575-579
137. Giamarellos-Bourboulis EJ, Raftogiannis M, Antonopoulou A, Baziaka F,
Koutoukas P, Savva A, Kanni T, Georgitsi M, Pistiki A, Tsaganos T, Pelekanos N,
Athanassia S, Galani L, Giannitsioti E, Kavatha D, Kontopidou F, Mouktaroudi M,
Poulakou G, Sakka V, Panagopoulos P, Papadopoulos A, Kanellakopoulou K,
Giamarellou H. Effect of the novel influenza A (H1N1) virus in the human immune
system. PLoS One 2009; 4: e8393
14
138. Tsangaris I, Plachouras D, Kavatha D, Gourgoulis GM, Tsantes A, Kopterides P,
Tsankis G, Dimopoulou I, Orfanos S, Giamarellos-Bourboulis EJ, Giamarellou H,
Armaganidis A. Diagnostic and prognostic value of procalcitonin among febrile critically
ill patients with prolonged ICU stay. BMC Infectious Diseases 2009; 9: 213
139. Kanellakopoulou K, Sahinides T, Tsaganos T, Galanakis N, Giamarellou H,
Giamarellos-Bourboulis EJ. In vitro elution of moxifloxacin from cancellous bone
allografts. Journal of Biomedical Material Research Part A 2010; 92: 52-55
140. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, Livaditi O, Pelekanou A,
Tsagarakis S, Armaganidis A, Orfanos SA. Ex-vivo effect of dexamethasone on
cytokine production from whole blood of septic patients: correlation with disease
severity. Cytokine 2010; 49: 89-94
141. Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A,
Giamarellos-Bourboulis EJ. Long-term efficacy of etanercept in hidradenitis
suppurativa: results from an open-label phase II prospective trial. Experimental
Dermatology 2010; 19: 538-540
142. Kelekis NL, Efstathopoulos E, Balanika A, Spyridopoulos TN, Pelekanou A, Kanni
T, Savva A, Brountzos E, Giamarellos-Bourboulis EJ. Ultrasound aids in diagnosis
and severity assessment of hidradenitis suppurativa. British Journal of Dermatology
2010; 162: 1400-1402
143. Koutelidakis I, Bezirtzoglou E, Giamarellos-Bourboulis EJ, Grosomanidis V,
Kotzampassi K. Impact of synbiotics in intestinal flora of critically ill patients bearing
multiple injuries. International Journal of Antimicrobial Agents 2010; 36, 90-91
144. Papadopoulos A, Ferwerda B, Antodiadou A, Sakka V, Galani L, Kavatha D,
Panagopoulos P, Poulakou G, Kanellakopoulou, van der Meer JWM, GiamarellosBourboulis EJ, Netea MG. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms
are associated with increased infection risk in patients with advanced HIV-1 infection.
Clinical Infectious Diseases 2010; 51: 242-247
145. Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, Adamis
S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanassia S, Baziaka F,
Charalambous A, Christodoulou S, Dimopoulou I, Floros I, Giannitsioti E, Gkanas P,
Ioakeimidou A, Kanellakopoulou K, Karabela N, Karagianni V, Katsarolis I, Kontopithari
G, Kopterides P, Koutelidakis I, Koutoukas P, Kranidioti H, Lignos M, Louis K,
Lymberopoulou K, Mainas E, Marioli A, Massouras C, Mavrou I, Mpalla M, Michalia M,
Mylona H, Mytas V, Papanikolaou I, Papanikolaou K, Patrani M, Perdios I, Plachouras
D, Pistiki A, Protopapas K, Rigaki K, Sakka V, Sartzi M, Skouras V, Souli M, Spyridaki
A, Strouvalis I, Tsaganos T, Zografos G, Mandragos K, Klouva-Molyvdas P, Maggina
N, Giamarellou H, Armaganidis A, Giamarellos-Bourboulis EJ. Early alterations of the
innate and adaptive immune statuses is sepsis according to the type of underlying
infection. Critical Care 2010; 14: R96
146. Kumpf O, Giamarellos-Bourboulis EJ, Koch A, Hamann L, Mouktaroudi M, Oh
DY, Latz E, Lorenz E, Schwartz DA, Ferwerda B, Routsi C, Skalioti C, Kullberg BJ, van
der Meer JWM, Netea MG, Zacharowski K, Schumann RR. Influence of genetic
variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and
cytokine release: an observational study in three cohorts. Critical Care 2010; 14: R103
147. Koutsostathis S, Tsaganos T, Giamarellos-Bourboulis EJ, Kotsaki A, Papalois A,
Efstathopoulos N. Eicosapentaenoic acid prolongs survival and attenuates
inflammatory response in an experimental model of lethal trauma. Prostaglandins
Leukotrienes and Essential Fattys Acids 2010; 83: 69-74
148. Korakianitis I, Mirtsou V, Gougoudi E, Raftogiannis M, Giamarellos-Bourboulis
EJ. Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant
Stenotrophomonas maltophilia. International Journal of Antimicrobial Agents 2010; 36:
387-389
15
149. Kassi E, Dalamaga M, Hroussalas G, Kazanis, K, Merantzi G, Zachari A,
Giamarellos-Bourboulis EJ, Dionyssiou-Asteriou A. Adipocyte factors, high-sensitive
C-recative protein levels and lipoxidative stress products in overweight
postmenopausal women with normal and impaired OGTT. Maturitas 2010; 67: 72-77
150. Raftogiannis M, Antonopoulou A, Baziaka F, Spyridaki A, Koutoukas P, Tsaganos
T, Savva A, Pistiki M, Georgitsi M, Giamarellos-Bourboulis EJ. Indication for a role of
T-regulatory cells for the advent of influenza A (H1N1)-related pneumonia. Clinical and
Experimental Immunology 2010; 161: 576-583
151. Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H,
Giamarellos-Bourboulis EJ. Diagnostic value of triggering receptor expressed on
myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational
study. BMC Infectious Diseases 2010; 10: 286
152. Joosten LAB, Netea MG, Mylona E, Koenders MI, Malireddi RKS, Oosting M,
Stienstra R, van de Veerdonk FL, Stalenhoef AF, Giamarellos-Bourboulis EJ,
Kaneganti TD, van der Meer JWM. Engagement of fatty acids with toll-like receptor 2
drives interleukin-1β production via the ASC/caspase-1 pathway in monosodium urate
crystal-induced gouty arthritis. Arthritis and Rheumatism 2010; 62: 3237-3248
153. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni Th, Mouktaroudi M, Pantelidou I,
Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F,
Giannopoulos P, Giannikopoulos G, Gialvalis D, Gourgoulis GM, Kotzampassi K,
Katsifa K, Kofinas G, Kontopidou F, Koratzanis G, Koulouras V, Koutsikou A, Koupetori
M, Kritselis I, Leonidou L, Mega A, Mylona V, Nikolaou H, Orfanos S, Panagopoulos P,
Paramythiotou E, Papadopoulos A, Papanikolaou X, Pavlaki M, Polychronopoulos V,
Skoutelis A, Theodotou A, Vassiliaghou M, Douzinas EE, Gogos C, Armaganidis A.
Procalcitonin as an early indicator of outcome in sepsis: a prospective observational
study. Journal of Hospital Infection 2011; 77: 58-63
154. Douzinas EE, Betrosian A, Giamarellos-Bourboulis EJ, Tasoulis MK, Prigouris P,
Livaditi O, Andrianakis I, Goutas N, Vlachodimitropoulos D, Pelekanou A, Villiotou V,
Legakis I, Chrousos GP. Hypoxemic resuscitation from hemorrhagic shock prevents
lung injury and attenuates oxidative response and IL-8 overexpression. Free Radical
Biology and Medicine 2011; 50: 245-253
155. Giamarellos-Bourboulis EJ, van de Veerdonk, Mouktaroudi M, Raftogiannis M,
Antonopoulou A, Joosten LAB, Pickkers P, Savva A, Georgitsi M, van der Meer JWM,
Netea MG. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental
endotoxemia. Critical Care 2011; 15: R27
156. Vaki I, Kranidioti H, Karagianni V, Spyridaki A, Kotsaki A, Routsi C, GiamarellosBourboulis EJ. An early circulating factor in severe sepsis modulates apoptosis of
monocytes and lymphocytes. Journal of the Leukocyte Biology 2011; 89: 343-349
157. Souli M, Konstantinidou E, Tzepi I, Tsaganos T, Pefanis A, Chryssouli Z, Galani I,
Giamarellos-Bourboulis EJ, Giamarellou H. Efficacy of carbapenems against a
metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intraabdominal abscess model. Journal of Antimicrobial Chemotherapy 2011; 66: 611-617
158. Atmatzidis S, Koutelidakis I, Chatzimavroudis G, Louis K, Pistiki A, Roditis K,
Atmatzidis K, Giamarellos-Bourboulis EJ. Clarithromycin modulates immune
responses in experimental peritonitis. International Journal of Antimicrobial Agents
2011; 37: 347-351
159. Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ,
Mercier E, Garbino J, Luyt CE, Chastre J, Georgescu-Kyburz V, Rudolf MP, Gafner V,
L azar H, Koch H, Perez A, Krämer SD, Tamm M. Pharmacokinetics and safety of
panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial
Pseudomonas aeruginosa O11 pneumonia. Journal of Antimicrobial Chemotherapy
2011, 66: 1110-1116
16
160. Korovesi I, Papadomichelakis E, Orfanos SE, Giamarellos-Bourboulis EJ, Livaditi
O, Pelekanou A, Sotiropoulou C, Koutsoukou A, Dimopoulou I, Ekonomidou F, Psevdi
E, Armaganidis A, Roussos C, Marczin N, Kotanidou A. Exhaled breath condensate in
mechanically ventilated brain-injured patients with no lung injury or sepsis.
Anesthesiology. 2011, 114: 1118-1129
161. Tsiolis P, Giamarellos-Bourboulis EJ, Mavrogenis AF, Savvidou O, Lallos SN,
Frangia K, Lazarettos I, Nikolaou V, Efstathopoulos NE. Experimental osteomyelitis
caused by methicillin-resistant Staphylococcus aureus treated with a polylactide carrier
releasing linezolid. Surgical Infections 2011, 12: 131-135
162. Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M,
Raftogiannis M, Antonakos N, Apostolidou E, Carrer DP, Dimopoulos G, Economou A,
Efthymiou G, Galanakis N, Galani L, Gargalianos P, Karaiskos I, Katsenos C, Kavatha
D, Koratzanis E, Labropoulos P, Lada M, Nakos G, Paggalou E, Panoutsopoulos G,
Paraschos M, Pavleas I, Pontikis K, Poulakou G, Prekates A, Sybardi S,
Theodorakopoulou M, Trakatelli C, Tsiaoussis P, Gogos C, Giamarellou H,
Armaganidis A, Meisner M. Early changes of procalcitonin may advise about prognosis
and appropriateness of antimicrobial therapy in sepsis. Journal of Critical Care 2011,
26: 331.e1-331-e7
163. Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I,
Kotsaki A, Polychronopoulos V. Impact of multidrug resistance on experimental
empyema by Pseudomonas aeruginosa. Respiration 2011, 82: 46-53
164. Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P,
Tsaganos T, Kotanidou A, Apostolidou E, Giamarellos-Bourboulis EJ, Dimopoulos G.
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease
severity in ventilator-associated pneumonia and sepsis. Journal of Infection 2011, 63:
344-350
165. Rosenthul DC, Plantiga TS, Papadopoulos A, Joosten LAB, Antoniadou A,
Venselaar H, Kullberg BJ, van der Meer JWM, Giamarellos-Bourboulis EJ, Netea
MG. Variation in genes of β-glucan recognition pathway and susceptibility to
opportunistic infections in HIV-positive patients. Immunological Investigations 2011, 40:
735-750
166. Mylona V, Koussoulas V, Tzivras D, Makrygiannis E, Georgopoulou P, Koratzanis
G, Giamarellos-Bourboulis EJ, Tzivras M. Changes in adaptive and innate immunity
in patients with acute pancreatitis and systemic inflammatory response syndrome.
Pancreatology 2011, 11: 475-481*
167. Koussoulas V, Giamarellos-Bourboulis EJ, Barbatzas C, Pimentel M. Serum
sTREM-1 as a asurrogate marker of treatment outome in patients with peptic ulcer
disease. Digestive Diseases and Sciences 2011, 56: 3590-3595
168. Chatziantoniou I, Giamarellos-Bourboulis EJ, Diakos G, Lallos SN, Tsaganos T,
Korres DS, Efstathopoulos NE. Serum kinetics of soluble triggersing receptor
expressed on myeloid cells-1 differs in relation to the type of arthroplasty Biomarkers
2011, 16: 600-604
169. Koutsostathis S, Tsaganos T, Lallos S, Georgitsi M, Roumeliotis L, GiamarellosBourboulis EJ, Efstathopoulos NE. Early increase of serum angiopoietin-2 are
associated with early progression to death in experimental injury. Cytokine 2011, 56:
817-822
170. Poukoulidou T, Spyridaki A, Michailidou I, Kopterides P, Pistiki A, Alexiou Z,
Chrisofos M, Dimopoulou I, Drimoussis P, Giamarellos-Bourboulis EJ, Koutelidakis I,
Marioli A, Mega A, Orfanos SE, Theodorakopoulou M, Tsironis C, Maggina N,
Polychronopoulos V, Tsangaris I. TREM-1 expression on neutrophils and monocytes of
septic patients: relation to the underlying infection and the implicated pathogen. BMC
Infectious Diseases 2011, 11: 309
17
171. Atmatzidis S, Koutelidakis IM, Chatzimavroudis G, Kotsaki A, Louis K, Pistiki A,
Savva A, Antonopoulou A, Atmatzidis K, Giamarellos-Bourboulis EJ. Detrimental
effect of apoptosis of lymphocytes at an early time point of experimental abdominal
sepsis. BMC Infectious Diseases 2011, 11: 321
172. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C,
Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by
small bowel culture: relationship with irritable bowel syndrome. Digestive Diseases and
Science 2012, 57: 1321-1329
173. Gkiza E, Giamarellos-Bourboulis EJ, Tsaganos T, Xanthos T, Korou LM, Carrer
DP, Stergiopoulos S, Kouskouni E, Perrea DN, Dontas IA. Isolation of aerobic bacteria
in interval specimens from domesticated pigs used in biomedical research and the
association with bacterial translocation. Journal of Animal and Veterinary Advances
2012, 11: 539-546
174. Antonopoulou A, Baziaka F, Tsaganos T, Raftogiannis M, Koutoukas P, Spyridaki
A, Mouktaroudi M, Kotsaki A, Savva A, Georgitsi M, Giamarellos-Bourboulis EJ.
Role of tumor necrosis factor gene single nucleotide polymorphisms in the natural
course of 2009 influenza A H1N1 virus infetion. International Journal of Infectious
Diseases 2012, 16: e204-e208
175. Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kostaki A, Kardara M,
Orfanos SE, Kotanidou A, Giamarellos-Bourboulis EJ. Early serum levels of soluble
triggersing receptor expressed on myeloid cells-1: correlation with monocyte gene
expression. Journal of Critical Care 2012, 27: 294-300
176. Spyridaki A, Raftogiannis M, Antonopoulou A, Tsaganos T, Routsi C, Baziaka F,
Karagianni M, Mouktaroudi M, Koutoukas P, Pelekanou A, Kotanidou A, Orfanos SE,
van der Meer JWM, Netea MG, Giamarellos-Bourboulis EJ. Effect of clarithromycin
in inflammatory markers of patients with ventilator-associated pneumonia and sepsis
caused by Gram-negative bacteria: results from a randomized clinical study.
Antimicrobial Agents and Chemotherapy 2012, 56: 3819-3825
177. Kotsaki A, Raftogiannis M, Routsi C, Baziaka F, Kotanidou A, Antonopoulou A,
Orfanos SE, Katsenos C, Koutoukas P, Plachouras D, Mandragos K, GiamarellosBourboulis EJ. Genetic polymorphisms within tumor necrosis factor gene promoter
region: a role for susceptibility to ventilator-associated pneumonia. Cytokine 2012, 59:
358-363
178. Mylona EE, Mouktaroudi M, Crisan TO, Makri S, Pistiki A, Georgitsi M, Savva A,
Netea MG, van der Meer, Giamarellos-Bourboulis EJ, Joosten LAB. Enhances
interleukin-1β production of PBMCs from patients with gout after stimulation with Tolllike receptor-2 ligands and urate crystals. Arthritis Research and Therapy 2012, 14:
R158
179. Quintin J, Saeed S, Martens JHA, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C,
Jacobs L, Jansen T, Kullberg BJ, Wijmenga C, Joosten LAB, Xavier RJ, van der Meer
JWM, Stunnenberg HG, Netea MG. Candida albicans infection affords protection
against reinfection via functional reprogramming of monocytes. Cell Host and Microbe
2012, 12: 223-232
180. Papadopoulos AI, Ferwerda B, Antoniadou A, Sakka V, Galani L, Kavatha D,
Panagopoulos P, Poulakou G, Protopapas K, van der Meer JWM, Netea MG,
Giamarellos-Bourboulis EJ. Association of the Mal/TIRAP S180L variant
polymorphism with decreased infection risk in patients with advanced HIV-1 infection.
Cytokine 2012, 60: 104-107
181. Tzepi IM, Giamarellos-Bourboulis EJ, Carrer DP, Tsaganos T, Claus RA, Vaki I,
Pelekanou A, Kostaki A, Tzortzioti V, Topouzis S, Bauer M, Papapetropoulos A.
18
Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant
Pseudomonas aeruginosa. Journal of Pharmacology and Experimental Therapeutics
2012, 343: 278-287
182. Sponholz C, Huse K, Kramer M, Giamarellos-Bourboulis EJ, Claus RA, Kern A,
Engel C, Kuhnt E, Kiehntopf M, Routsi C, Mylona V, Tsangaris I, Heinemann SH,
Reinhart K, Platzer M, Bauer M. Gene polymorphisms in the heme degradation
pathway and outcome of severe human sepsis. Shock 2012, 38: 459-465
183. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I,
Dimopoulou I, Mouktaroudi M, Raftogannis M, Georgitsi M, Linnér A, Adamis G,
Antonopoulou A, Apostolidou E, Chrisofos M, Katsenos C, Koutelidakis I, Kotzampassi
K, Koratzanis G, Koupetori M, Kritselis I, Lymberopoulou K, Mandragos K, Marioli A,
Sundén-Kullberg J, Mega A, Prekates A, Routsi C, Gogos C, Treutiger CJ,
Armaganidis A, Dimopoulos G. Risk assessment in sepsis: a new prognostication
score by APACHE II score and serum soluble urokinase plasminogen activator
receptor. Critical Care 2012, 16: R149
184. van de Veerdonk FL, Mouktaroudi M, Ramakers BP, Pistiki A, Pickkers P, van der
Meer JWM, Netea MG, Giamarellos-Bourboulis EJ. Deficient Candida-specific Thelper 17 response during sepsis. Journal of Infectious Diseases 2012, 206: 17981802
185. Grech I, Giatrakou S, Damoraki G, Pistiki A, Kaldirmidis P, GiamarellosBourboulis EJ, Stavrianeas N. Single nucelaotide polymorphisms of Toll-like receptor4 protect against acne conglobata. Journal of the European Academy of Dermatology
and Venereology 2012, 26: 1538-1543
186. Tzermpos F, Iatrou I, Papadimas C, Pistiki A, Georgitsi M, GiamarellosBourboulis EJ. Function of blood monocytes among patients with orofacial infections.
Journal of Cranio-Macillo-Facial Surgery 2013, 41: 88-91
187. Savva A, Kanni T, Damoraki G, Kotsaki A, Giatrakou S, Katoulis A, Papadavid E,
Giamarellos-Bourboulis EJ. Impact of Toll-like receptor-4 and tumour necrosis factor
gene polymorphisms in patients with hidradenitis suppurativa. British Journal of
Dermatology 2013, 168: 311-317
188. Toufekoula S, Papadakis V, Tsaganos T, Routsi C, Orfanos SE, Kotanidou A,
Carrer DP, Rafotgiannis M, Baziaka F, Giamarellos-Bourboulis EJ.
Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant Gramnegative bacteria: experimental and clinical evidence. Critical Care 2013, 17: R6
Review articles
1. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery
of antibiotics in bone infections. Drugs 2000; 59: 1223-1232.
2. Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, Giamarellou H. An update on the
etiology and diagnostic evaluation of a leukemoid reaction. European Journal of
Internal Medicine 2006; 17: 394-398
3. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a
class of potent immunomodulators. International Journal of Antimicrobial Agents 2008;
31: 12-20
4. Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis
EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J,
Zouboulis CC. What causes hidradenitis suppurativa? Commentary 1. Experimental
Dermatology 2008; 17: 455-472
19
5. Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected
effects with macrolides. International Journal of Antimicrobial Agents 2008; 32S: S39S43
6. Karantonis FF, Nikiteas N, Vlachou A, Giamarellos-Bourboulis EJ, Tsigris C, Kostakis
A. Evaluation of the effects of laparotomy and laparoscopy on the immune system in
intra-abdominal sepsis: a review. Journal of Investigative Surgery 2008; 21: 330-339
7. Giamarellos-Bourboulis EJ, Scheinfeld N, Pelekanou A. Hidradenitis suppurativa as a
chronic inflammatory disorder: are biological therapies the future therapeutic solution?
Expert Reviews of Dermatology 2009; 4: 47-54
8. Giamarellos-Bourboulis EJ. Macrocycle molecules for the management of systemic
infections: the clarithromycin paradigm Current Topics in Medicinal Chemistry 2010; 10:
1470-1475
9. Giamarellos-Bourboulis EJ. What is the pathophysiology of the septic host upon
admission? International Journal of Antimicrobial Agents 2010; 36 Supplement: S2-S5
10.Antonopoulou A, Giamarellos-Bourboulis EJ. Immunomodulation in sepsis: state of
the art and future perspective. Immunotherapy 2011; 3: 117-128
11.Giamarellos-Bourboulis EJ. Angiopoietins in sepsis: biomarkers or effector
molecules? Critical Care Medicine 2011, 39: 890-891
12.Mouktaroudi M, Giamarellos-Bourboulis EJ. Macrolides for the therapy of nosocomial
infections Current Opinion in Infectious Diseases 2012, 25: 205-210
13.Kotsaki A, Giamarellos-Bourboulis EJ. Molecular diagnosis of sepsis Expert Opinion
οn Medical Diagnostics 2012, 6: 209-219
14.Giamarellos-Bourboulis EJ, Raftogiannis M. The immune response to severe
bacterial infections: consequences for therapy Expert Review Antiinfective Therapy
2012, 10: 369-380
15.Kotsaki A, Giamarellos-Bourboulis EJ. Emerging drugs for the treatment of sepsis
Expert Opinion Emerging Drugs 2012, 17: 379-391
16.Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: more
drugs, less dietary supplementation International Journal of Antimicrobial Agents 2012,
40: 288-296
20
Chapters in collective volumes
1. Giamarellos-Bourboulis EJ. Use of oleuropein in experimental sepsis by
Pseudomonas aeruginosa. In Preedy VR, Watson RR (eds) Olives and olive oil in
health and disease prevention. Elsevier Academic Press 2010: 1321-1325
2. Giamarellos-Bourboulis EJ. Pathogenesis of sepsis as related to novel therapeutic
concepts. In Naber KG, Scaeffer AJ, Heyns CF, Matsumoto T, Shoskes DA, BjeklundJohansen TE (eds). Urogenital infections. European Association of Urology 2010: 604614
3. Giamarellos-Bourboulis EJ. The control of multidrug-resistant Pseudomonas
aeruginosa: insights into epidemiology and management. In Gould IM, van der Meer
JWM (eds). Antibiotic policies. Spinger Science and Business Media 2011: 127-140
Granted patents
1. “sTREM-1 in serum as an index of therapeutic resolution of peptic ulcer disease”.
Ministry of Industrial Commerce, September 2007
Invited presentations to internationally established conferences
1. Experimental studies with Pseudomonas aeruginosa, State-of-the-Art Lecture 5th
European Congress of Chemotherapy and Infection, 19 October 2003, Rhodes,
Greece
2. Lessons to be learned from animals and ex vivo models, Symposium “Should We Use
Local Antibiotics In The Treatment of Bone Infections” 6th European Congress of
Chemotherapy, 3 December 2004, Paris, France
3. Role of macrolides for the management of infections by Pseudomonas spp and of
severe infections, Symposium “New and old drugs for serious infections” 7th European
Congress of Chemotherapy and Infection, 20 October 2005, Florence, Italy
4. Νew perspectives of immunointervention in sepsis, Symposium “Sepsis 2006” 8th
European Congress of Chemotherapy and Infection, 27 October 2006, Budapest,
Hungary
5. Anti-TNF strategies for the management of hidradenitis suppurativa, Course “Infectious
Diseases of the Skin: Advanced” 16th Congress of the European Academy of
Dermatology and Venereology, 17 May 2007, Vienna, Austria
6. Novel perspectives of immunointervention in sepsis. 13th International Symposium on
Infections in the Critically Ill Patient, 23 February 2008, Athens, Greece
7. 4 talks entitled “Role of monocyte apoptosis; Clarithromycin; Greece is a night mare of
resistance; TLR4 genetics” at the 29th International Symposium on Intensive Care and
Emergency Medicine, 24-28 March 2009, Brussels, Belgium
8. The need for immunointervention in sepsis: novel perspectives with clarithromycin. 19th
European Congress of Clinical Microbiology and Infectious Diseases, 18 May 2009,
Helsinki, Finland
9. New antibiotic targets-virulence and quorum sensing. Symposium “The problem of
antibiotic resistance, superbugs and the need for new drugs-Part A” 8th World
Congress on Trauma, Shock, Inflammation and Sepsis-TSIS 2010, 11 March 2010,
Munich, Germany
10. Macrolides have a role in respiratory infections beyond their antimicrobial activity?
Symposium “Highlights in respiratory infections” European Respiratory Society Annual
Congress, 20 September 2010, Barcelona, Spain
11. 3 talks entitled “Clarithromycin for everyone? Towards better stratification; How to cope
with them in a region of multidrug resistance?” at the 31st International Symposium on
Intensive Care and Emergency Medicine, 22-26 March 2011, Brussels, Belgium
12. A patient admitted with hypotension. Session “Bacteremia and sepsis” 21st European
Congress of Clinical Microbiology and Infectious Diseases and 27th International
Congress of Chemotherapy 7 May 2011, Milan, Italy
21
13. Immunotherapy for respiratory infections: where we will stand in 2022. Session “Back
to the future” ESCMID Postgraduate Education Course “Innovation in severe acute
respiratory infections”, 13 January 2012, Sitges, Spain
Organization of international congresses
1. Chairman of the organizing committee, 4th European Conference on Bloodstream
Infections, May 27 and 28, Athens, Greece
2. Chairman of the organizing committee, 5th European Conference on Bloodstream
Infections, November 11 and 12, Limassol, Gyprus
International Prizes/Awards
1. Research Fellowship Award of the European Society of Clinical Microbiology and
Infectious Diseases at the 11th European Congress of Clinical Microbiology and
Infectious Diseases, April 2001, Istanbul, Turkey “The in vitro interaction of
polyunsaturated fatty acids and Gram-negative bacteria. Future perspectives for the
pathogenesis and treatment of Gram-negative sepsis”
2. Young Investigator Award for Research in Clinical Microbiology and Infectious
Diseases of the European Society of Clinical Microbiology and Infectious Diseases,
19th European Congress of Clinical Microbiology and Infectious Diseases, 17 May
2009, Helsinki, Finland
3. Chairman of the working group on Bloodstream Infections, International Society for
Chemotherapy
Membership of the editorial board of international journals
1. International Journal of Antimicrobial Agents (2008-today)
2. Infectious Diseases in Clinical Practice (2009-today)
3. Frontiers in Infectious Diseases (2012-today)

CURRICULUM VITAE Present Position Address Phone/Fax:

Transcription

Similar documents